RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 118 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.3%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,522 | -85.6% | 110 | -89.7% | 0.00% | – |
| Q2 2023 | $17,529 | +2082.9% | 1,063 | +2262.2% | 0.00% | – |
| Q1 2023 | $803 | -38.7% | 45 | 0.0% | 0.00% | – |
| Q4 2022 | $1,310 | +31.0% | 45 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 45 | -65.4% | 0.00% | – |
| Q1 2022 | $1,000 | -96.9% | 130 | -95.9% | 0.00% | – |
| Q4 2021 | $32,000 | +3100.0% | 3,164 | +3195.8% | 0.00% | – |
| Q3 2021 | $1,000 | -66.7% | 96 | -29.4% | 0.00% | – |
| Q2 2021 | $3,000 | -72.7% | 136 | -72.5% | 0.00% | – |
| Q1 2021 | $11,000 | -56.0% | 494 | -40.4% | 0.00% | – |
| Q4 2020 | $25,000 | +150.0% | 829 | +79.8% | 0.00% | – |
| Q3 2020 | $10,000 | +400.0% | 461 | +339.0% | 0.00% | – |
| Q2 2020 | $2,000 | -33.3% | 105 | +6.1% | 0.00% | – |
| Q1 2019 | $3,000 | – | 99 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 4,909,956 | $142,977,919 | 8.04% |
| Opaleye Management Inc. | 735,000 | $21,403,200 | 7.44% |
| Frazier Life Sciences Management, L.P. | 1,894,000 | $55,153,280 | 3.43% |
| RA Capital Management | 5,516,067 | $160,627,871 | 3.26% |
| Altium Capital Management LP | 170,000 | $4,950,400 | 2.52% |
| Samsara BioCapital, LLC | 345,293 | $10,054,932 | 2.16% |
| Rock Springs Capital Management LP | 1,760,865 | $51,276,389 | 1.23% |
| Parkman Healthcare Partners LLC | 157,862 | $4,596,941 | 1.22% |
| Baker Brothers Advisors | 6,354,608 | $185,046,185 | 1.11% |
| EAM Investors, LLC | 164,695 | $4,795,918 | 0.99% |